Skip to main content
SpringerLink
Log in

Personalized peginterferon plus ribavirin therapy maximizes viral suppression in patients with chronic hepatitis C

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Figure 1

References

  1. Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs 2008; 68(1): 27–42

    Article  PubMed  CAS  Google Scholar 

  2. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008; 25(1): 9–18

    Article  PubMed  CAS  Google Scholar 

  3. Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-α-2a plus ribavirin dose reductions and host-related factors. Clin Drug Invest 2008; 28(1): 9–16

    Article  CAS  Google Scholar 

  4. Maio G, D’Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine aminotransferase levels in the general population: a survey in a southern Italian town. J Hepatol 2000; 33: 116–20

    Article  PubMed  CAS  Google Scholar 

  5. National Institutes of Health consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002 Jun 10-12; 19(3): 1–46

    Google Scholar 

  6. Wong JB. Hepatitis C. Cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24(7): 661–72

    Article  PubMed  Google Scholar 

  7. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005 Apr; 41(4): 790–800

    Article  PubMed  Google Scholar 

  8. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002 Feb; 4(1): 23–30

    Article  PubMed  Google Scholar 

  9. Pedder SC. Pegylation of interferon alfa: structural and pharmaco-kinetic properties. Semin Liver Dis 2003; 23Suppl. 1: 19–22

    PubMed  Google Scholar 

  10. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 Apr; 126(4): 1015–23; discussion 947

    Article  PubMed  CAS  Google Scholar 

  11. Shiffman M, Morgan TR, Ghany MG, et al. The impact of Peginterferon (PEG) and ribavirin (RBV) dosing on sustained virological response (SVR) in patients undergoing retreatment in the HALT-C trial [abstract]. Hepatology 2004; 40 Suppl. 1: 314A

    Google Scholar 

  12. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 Jan; 132(1): 103–12

    Article  PubMed  CAS  Google Scholar 

  13. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 Oct; 123(4): 1061–9

    Article  PubMed  CAS  Google Scholar 

  14. Snoeck E, Wade JR, Duff F, et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62: 699–709

    Article  PubMed  CAS  Google Scholar 

  15. Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin non-responder patients. Gastroenterology 2006 Apr; 130(4): 1098–106

    Article  PubMed  CAS  Google Scholar 

  16. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998 Nov 19; 339(21): 1493–9

    Article  PubMed  CAS  Google Scholar 

  17. Cotler SJ, Layden JE, Neumann AU, et al. First phase hepatitis C viral kinetics in previous nonresponder patients. J Viral Hepat 2003 Jan; 10(1): 43–9

    Article  PubMed  CAS  Google Scholar 

  18. Lawitz EJ, Bala NS, Becker S, et al. Pegylated alfa-2b and ribavirin for hepatitis C patients who were non-responders to previous therapy [abstract]. Gastroenterology 2003; 124 Suppl. 1: A783

    Article  Google Scholar 

  19. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 Oct; 25(5): 472–92

    Article  PubMed  CAS  Google Scholar 

  20. White CL, Malet P, Wentworth C, et al. The TARGET trial: 48 wk HCV RNA results of a randomized trial of 1.5 µg/kg vs 3.0 µg/kg pegylated interferon alfa-2b (PEG) plus ribavirin (RBV) for naive chronic hepatitis C [abstract]. Hepatology 2004; 40Suppl. 1: 400A

    Google Scholar 

  21. Malet P, White CL, Wentworth C, et al. The TARGET trial: 48 wk HCV RNA results of a randomized trial of 1.5 µg/kg vs 3.0 µg/kg pegylated interferon alfa-2b (PEG) plus ribavirin (RBV) for non-responders (NR) and relapsers (Rs) to previous therapy [abstract]. Hepatology 2004; 40Suppl. 1: 400A

    Google Scholar 

  22. Myers RP, Poynard T. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2002; (4): CD003617

    PubMed  Google Scholar 

  23. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004 Mar 15; 189(6): 964–70

    Article  PubMed  CAS  Google Scholar 

  24. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 Apr; 130(4): 1086–97

    Article  PubMed  CAS  Google Scholar 

  25. Afdhal N, Freilich B, Levine R, et al. Colchine versus Peg-Intron long term (Copilot) trial: interim analysis of clinical outcomes at year 2 [abstract]. Hepatology 2004; 40Suppl. 1: 239A

    Google Scholar 

  26. Poynard T, Schiff E, Terg K, et al. High early viral response (EVR) with peg-intron/rebetol (PR) weight based dosing in previous interferon/ribavirin HCV treatment failures: early results of the EPIC3 trial [abstract]. Hepatology 2004; 40Suppl. 1: 238A

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Personalized peginterferon plus ribavirin therapy maximizes viral suppression in patients with chronic hepatitis C. Drugs Ther. Perspect 24, 18–21 (2008). https://doi.org/10.2165/00042310-200824070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824070-00005

Search

Navigation